Adding semaglutide to usual care is projected to avert 358,400 major adverse cardiovascular events at a cost of $148,100 per QALY gained in US adults without diabetes.
Oral sodium chloride supplements in heart failure patients increased serum and urinary sodium concentrations but did not affect clinical outcomes or body weight.
Higher peak metabolic equivalents (METs) on exercise treadmill stress testing were associated with lower all-cause death (HR 0.86; p=0.025) in chronic coronary disease patients.
In RCTs of long-term pharmacological therapy after ACS, treatment efficacy was comparable between sexes, regardless of female representation (REM mean difference 0.00, P = 0.98).
Premenopausal women with acute coronary syndrome have worse outcomes than young men and often receive less guideline-directed therapies.
Abelacimab significantly reduced major or clinically relevant nonmajor bleeding compared to rivaroxaban in patients aged 75 years or older (HR 0.32).
Activation of brain LepR protects the heart after ischemia-reperfusion injury by promoting BAT-derived EVs enriched with microRNA-29c-3p.
Patients with myocardial infarction due to isolated coronary artery ectasia had a 2.07-fold higher risk of recurrent MI compared to those without CAE (P =0.029).
In-hospital STEMI patients had a 25.9% mortality rate and significantly longer times to intervention compared to preadmission STEMI patients, with major complications more prevalent.
In a study of 8599 older adults, 55 novel protein markers of heart failure and 7 possibly causal proteins were identified and replicated across cohorts.